READING, Pa.--(BUSINESS WIRE)--SAI MedPartners (“SAI”), a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce that it has acquired IDEA Pharma (“IDEA”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022..

宾夕法尼亚州雷丁市——（商业新闻短讯）——SAI MedPartners（“SAI”）是一家为制药、生物技术和医疗器械行业提供战略见解和分析的全球咨询公司，很高兴宣布其收购了IDEA Pharma（“IDEA”）。Northlane Capital Partners（“NCP”）于2022年6月与管理层合作收购SAI。。

IDEA, headquartered in London, United Kingdom, specializes in pharmaceutical path-to-market strategy and innovation. This acquisition strengthens SAI’s capacity to offer comprehensive strategic services to its biopharma clients, supporting the process from drug discovery to market launch and lifecycle management..

IDEA总部位于英国伦敦，专注于制药市场战略和创新。此次收购增强了SAI向其生物制药客户提供全面战略服务的能力，支持了从药物发现到市场推出和生命周期管理的过程。。

Integrating IDEA’s expertise in early-phase positioning, clinical development, and commercialization with SAI’s extensive knowledge and expertise in competitive intelligence, market research, and market access consulting services will create a unique value proposition for biopharma clients. The collaboration will provide clients with an unmatched blend of market foresight, strategic creativity, and decision-support services to help develop and launch more great medicines..

将IDEA在早期定位、临床开发和商业化方面的专业知识与SAI在竞争情报、市场研究和市场准入咨询服务方面的广泛知识和专业知识相结合，将为生物制药客户创造独特的价值主张。此次合作将为客户提供无与伦比的市场远见、战略创造力和决策支持服务，以帮助开发和推出更多优秀药物。。

Erik Nordhoy, CEO of SAI, commented, “The addition of IDEA to the SAI organization brings incredible management talent and demonstrated thought leadership regarding strategic positioning and commercialization of new therapies. The strategic fit with our existing service offerings materially enhances our ability to serve as a key partner to our clients.”.

SAI首席执行官埃里克·诺德霍伊（Erik Nordhoy）评论道：“SAI组织理念的加入带来了难以置信的管理人才，并在新疗法的战略定位和商业化方面展示了思想领导力。与我们现有服务的战略契合大大增强了我们作为客户关键合作伙伴的能力。”。

Mike Rea, Founder and CEO of IDEA, added, “We are excited to join forces with SAI. Together, we will be better positioned to drive real innovation and impact for patients worldwide.”

IDEA创始人兼首席执行官迈克·雷亚（MikeRea）补充道：“我们很高兴能与SAI携手合作。我们将更好地推动真正的创新，并对全球患者产生影响。”

IDEA marks SAI’s third strategic acquisition, building on its successful partnerships with Fulcrum Research Group in 2022 and PharmaForce International in 2023.

。

ABOUT SAI MEDPARTNERS

关于SAI MEDPARTNERS

SAI is a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Reading, Pennsylvania, SAI provides best-in-class competitive intelligence and strategy support services to assist its clients across the product development lifecycle.

SAI是一家全球咨询公司，为制药、生物技术和医疗器械行业提供战略见解和分析。SAI总部位于宾夕法尼亚州雷丁，提供一流的竞争情报和战略支持服务，在整个产品开发生命周期中为客户提供帮助。

SAI works with leading multinational pharmaceutical companies, in addition to a growing number of biotechnology and medical device companies. SAI has a presence across the United States, Europe, and Asia. For more information, please visit www.sai-med.com..

SAI与领先的跨国制药公司以及越来越多的生物技术和医疗器械公司合作。SAI的业务遍及美国、欧洲和亚洲。有关更多信息，请访问www.sai-med.com。。

ABOUT IDEA PHARMA

关于IDEA PHARMA

IDEA Pharma is a global practice specializing in pharmaceutical path-to-market strategy and innovation. IDEA is headquartered in London, United Kingdom, with employees across Europe and the United States. For more information, please visit www.ideapharma.com.

IDEA Pharma是一家专门从事制药市场战略和创新的全球实践机构。IDEA总部位于英国伦敦，员工遍布欧洲和美国。有关更多信息，请访问www.ideapharma.com。

ABOUT NORTHLANE CAPITAL PARTNERS

关于NORTHLANE资本合伙人

Based in Bethesda, MD, NCP is a middle market private equity firm focused on key segments within the healthcare and business services sectors, where its principals have invested $1.7 billion of equity capital. NCP’s strategy is to partner with industry leading companies and great management teams, aligning incentives to accelerate growth and build value.

NCP总部位于马里兰州贝塞斯达，是一家中等市场私人股本公司，专注于医疗保健和商业服务部门的关键领域，其负责人已在这些领域投资了17亿美元的股本。NCP的战略是与业界领先的公司和优秀的管理团队合作，调整激励措施以加速增长和创造价值。

For more information, please visit www.northlanecapital.com..

有关更多信息，请访问www.northlanecapital.com。。